Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999060 | 0.77 | P2RY2 (0.40) | POLBP2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL20999063 | 0.77 | P2RY2 (0.39) | POLBP2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL20999061 | 0.76 | P2RY2 (0.39) | POLBP2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL25843145 | 0.74 | FBP1 (0.46) | P2RY6P2RY2 | |
| SCHEMBL14665773 | 0.72 | NT5E (0.36) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL22986143 | 0.69 | P2RY2 (0.40) | P2RY6P2RY2P2RY4 | |
| SCHEMBL15689120 | 0.69 | P2RY2 (0.44) | POLBP2RY6P2RY2P2RY4DUT | |
| SCHEMBL21016761 | 0.68 | FBP1 (0.38) | POLBP2RY6P2RY2P2RY4DUT | |
| SCHEMBL16382553 | 0.68 | P2RY2 (0.40) | POLBP2RY6P2RY2P2RY4DUT | |
| SCHEMBL19072605 | 0.67 | P2RY2 (0.40) | P2RY2P2RY4POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219994-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | Stemirna Therapeutics Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219994-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | RNMT, RNGTT, BCDIN3D | POLB 179/4885P2RY6 2965/4885P2RY2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.